Alnylam Pharmaceuticals Inc (ALNY)vsAstraZeneca PLC (AZN)
ALNY
Alnylam Pharmaceuticals Inc
$297.45
-1.02%
HEALTHCARE · Cap: $39.39B
AZN
AstraZeneca PLC
$187.03
+0.18%
HEALTHCARE · Cap: $286.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1310% more annual revenue ($60.44B vs $4.29B). AZN leads profitability with a 17.2% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.50. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$2401.68
Current Price
$297.45
$2104.23 discount
Margin of Safety
+4.8%
Fair Value
$194.77
Current Price
$187.03
$7.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 36.9x book value
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.1x leaves little room for execution misses.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ALNY profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.30 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 64/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?